Moreover, combined detection of MEF2D, ITGB1 and ITGB4 further identified a subpopulation of HCC patients with poorer prognosis (Figure 7C; Figure S10C, Supporting Information), suggesting that co‐detection of these three biomarkers represents a superior prognostic approach for HCC patients. This evidence concerns the gene MEF2D and hepatocellular carcinoma.